Asthma, Aspirin-Induced Clinical Trial
Official title:
Challenge Test for Acetylsalicylic Acid Hypersensitivity
The investigators want to find new challenge test for Acetylsalicylic hypersensitivity / Aspirin hypersensitivity. The investigators suggest that this new test will be as efficient as the already established protocols in terms of sensitivity and specificity.
Hypersensitivity to Acetylsalicylic Acid or Aspirin (and other NSAIDS) is a condition that affects up to 2,5% of the population. Most cases are seen in a complex of such hypersensitivity with chronic eosinophilic rhinosinusitis with nasal polyposis and asthma. Despite research in finding a reliable in-vitro-test for the condition, challenge tests are still considered gold standard. So far oral, nasal, inhalation and intravenous routes of administration has been described in literature. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01320072 -
Diagnosis of Aspirin Hypersensitivity in Aspirin Exacerbated Respiratory Disease
|
||
Completed |
NCT01867281 -
The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases
|
Phase 4 | |
Completed |
NCT02824523 -
Role of Inflammatory Mediators in AERD
|
||
Active, not recruiting |
NCT03028350 -
Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
|
Phase 2 | |
Completed |
NCT01597375 -
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease (Aspirin)
|
Phase 2 | |
Recruiting |
NCT04823585 -
Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab)
|
N/A | |
Recruiting |
NCT05575037 -
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
|
Phase 2 | |
Completed |
NCT03326063 -
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
|
Phase 2 |